Intuitive Surgical stock trades below consensus as da Vinci growth supports long-term story.
Published on 08/25/2026 at 07:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Intuitive Surgical Inc. (US46120E6023) stock is trading below prevailing analyst price targets even as its da Vinci robotic systems continue to drive double-digit revenue and market-cap growth as of August 25, 2026. Per recent market data, Intuitive Surgical is valued at more than $140 billion, reflecting strong investor confidence in the long-term demand for minimally invasive surgery.
Stock valuation and current market data
For investors, one key reference point is the consensus price target on Intuitive Surgical stock, which stands at $478.01 and implies a 26 percent potential return from recent trading levels as of August 24, 2026. A recent analyst overview notes that the shares were changing hands at $379.30 per share on that date, equating to a forward price-to-earnings multiple of 33.1. This gap between the current price and the $478.01 target highlights that analysts still see room for upside based on Intuitive Surgical's earnings trajectory.
Supporting this valuation, recent sector data from a Chinese market commentary cites Intuitive Surgical's market capitalization above $140 billion as of August 19, 2026, underlining how the company has grown into one of the largest players in global medical technology. The same analysis points out that the share price has increased nearly fivefold over the past decade, a performance that exceeds many traditional healthcare peers and reveals the structural tailwind behind surgical robotics.
Short-term price action has been more muted compared with that long-term run, as evidenced by a late-August quote snapshot. A real-time shares overview shows Intuitive Surgical at $373.57 per share as of August 25, 2026, 00:17 UTC, down $5.24 on the session and corresponding to a daily decline of 1.38 percent. The same snapshot lists a 12.24 percent gain over a recent performance interval and deeper drawdowns over longer horizons, indicating that while the stock has corrected from prior highs it still retains positive momentum over the medium term.
Latest fundamentals and revenue mix
From a fundamentals perspective, Intuitive Surgical's most recent full fiscal-year metrics revolve around the strength of its instruments, accessories, and services business tied to da Vinci systems. According to a sector review translated from Chinese, in fiscal 2025 the company generated $7.6 billion of revenue from instruments, accessories, and services, representing 75 percent of total revenue that year. That review emphasizes how recurring revenue linked to procedure volume and maintenance has become the core driver of the business model.
The same source underscores the historical growth profile by noting that Intuitive Surgical's share price has expanded nearly fivefold over the past ten years, anchored by steadily rising procedure counts and expanding indications for robotic-assisted surgery. While the article does not break out quarterly figures for 2026, it confirms that the 2025 revenue mix tilted heavily toward recurring streams, offering a buffer against cyclical swings in capital equipment orders.
Looking at valuation versus fundamentals, the forward P/E multiple of 33.1 cited in the August 24, 2026 analyst commentary is high compared with many diversified healthcare and medical-device companies. However, the 26 percent implied upside to the $478.01 consensus price target suggests that the market has not fully priced in expected growth in procedure volumes and da Vinci system placements over the next few years. Investors who focus on long-term cash flow have to weigh that premium valuation against the durability of Intuitive Surgical's competitive positioning.
Robotic surgery demand and external ecosystem signals
Beyond headline revenue figures, recent developments in the broader robotic surgery ecosystem shine a light on how Intuitive Surgical's technology is being adopted and integrated globally. On August 24, 2026, a report from India described the arrival of a US-made Xi Experience Centre mobile unit at the Bhopal Memorial Hospital and Research Centre to support robotic surgery training. The report explained that this experience centre is designed around Intuitive's da Vinci Surgical System, highlighting capabilities such as multi-quadrant access, real-time imaging, and advanced instrumentation.
These kinds of training initiatives contribute indirectly to Intuitive Surgical's growth metrics. As more surgeons become familiar with da Vinci platforms through dedicated experience centres, hospitals tend to increase procedure volumes, which in turn drives higher consumption of instruments and accessories. That feedback loop reinforces the importance of the recurring revenue segments that accounted for $7.6 billion, or three quarters of total revenue, in fiscal 2025, providing a clear bridge between ecosystem investment and financial outcomes.
Another external sign of Intuitive Surgical's influence can be seen in commentary from Surgical Science Sweden AB, which provides simulation and training solutions for robotic and minimally invasive surgery. In its second-quarter 2026 earnings highlights released August 19, 2026, the company reported SEK255 million of revenue, up 22 percent year-over-year, and disclosed that expected Intuitive-related revenue loss for 2026 had narrowed below a prior SEK60-90 million estimate due to higher dV5 attach rates and full renewal of My Intuitive Plus contracts. That earnings summary shows how third-party providers around Intuitive's ecosystem are tracking metrics like da Vinci 5 attach rates and subscription renewals, offering investors another window into demand for Intuitive's latest platform generation.
For shareholders, the mention of dV5 attach rates and My Intuitive Plus renewals matters because it signals sustained engagement with Intuitive's newer technology stack. High attach rates mean that customers are upgrading or extending their use of the latest systems, which can support both upfront capital sales and higher-margin recurring revenue streams through more complex instrumentation and data services. The narrowing of expected revenue loss for a partner company tied to Intuitive's platform also suggests that the pace of transition between system generations is stabilizing in favor of broader adoption.
Business model and representative product
Intuitive Surgical's business model centers on enabling minimally invasive surgery across multiple specialties through the da Vinci family of robotic-assisted surgical systems. The hardware platforms are sold to hospitals and surgical centers, but the longer-term economics depend on ongoing usage, instrument turnover, and service contracts. The fiscal 2025 figure of $7.6 billion in instruments, accessories, and services revenue - equal to 75 percent of total revenue that year - illustrates how the company has successfully shifted toward a model driven by recurring cash flows rather than one-off equipment placements.
A representative product within this ecosystem is the da Vinci Xi Surgical System, which has been featured in the Xi Experience Centre training vehicle deployed to Indian hospitals. According to the coverage of that training initiative, the Xi system supports multi-quadrant access, allowing surgeons to operate across different regions of the body without repositioning large segments of the equipment, while delivering real-time imaging to enhance precision. Advanced instrumentation tailored to specific procedures further expands the range of surgeries that can be performed robotically, from urology and gynecology to thoracic and general surgery.
For hospitals, investing in systems like da Vinci Xi carries significant capital expenditure, but the potential benefits include shorter patient stays, reduced complications, and higher operating-room throughput. These benefits can translate into economic value that supports the cost of instruments and accessories over time. As procedure volumes increase, Intuitive Surgical's recurring revenue grows in tandem, feeding back into the valuation discussion around the $478.01 consensus price target and the roughly $379-374 trading range observed in late August 2026.
Closing view on Intuitive Surgical stock
As of August 25, 2026, Intuitive Surgical stock is quoted at $373.57 in a real-time shares overview, representing a daily loss of 1.38 percent but sitting not far below the $379.30 per-share level cited in the August 24, 2026 analyst commentary. The latest quote snapshot confirms that the shares have delivered double-digit performance over a recent interval despite volatility, while the consensus target of $478.01 leaves a 26 percent implied upside if earnings and procedure growth unfold as expected.
For US retail investors, the key takeaway is that Intuitive Surgical combines a large $140 billion-plus market capitalization with a business model heavily weighted toward recurring revenue, highlighted by $7.6 billion of instruments, accessories, and services revenue representing 75 percent of total revenue in fiscal 2025. Against that backdrop, the current mid-$370s trading band and 33.1x forward P/E multiple must be assessed against both the upside implied by analyst targets and the operational evidence seen in da Vinci Xi deployments and ecosystem metrics such as dV5 attach rates and My Intuitive Plus renewals.
Fact box
Company: Intuitive Surgical Inc.
ISIN: US46120E6023
Ticker: ISRG
Exchange: Nasdaq
Price (as of August 25, 2026, 00:17 a.m. ET): $373.57 USD
Market cap: above $140 billion (as of August 19, 2026)
Sector / Industry: Health care / Medical devices and equipment
Index membership: S&P 500
